235 related articles for article (PubMed ID: 36933171)
21. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
22. Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma.
Marioni G; Nicolè L; Cazzador D; Pavone C; D'Avella D; Martini A; Mazzoni A; Zanoletti E
Head Neck; 2019 Oct; 41(10):3612-3617. PubMed ID: 31313389
[TBL] [Abstract][Full Text] [Related]
23. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
[TBL] [Abstract][Full Text] [Related]
24. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
25. Schwannomas exhibit distinct size-dependent gene-expression patterns.
Mehrian-Shai R; Freedman S; Shams S; Doherty J; Slattery W; Hsu NY; Reichardt JK; Andalibi A; Toren A
Future Oncol; 2015; 11(12):1751-8. PubMed ID: 26075443
[TBL] [Abstract][Full Text] [Related]
26. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
Louis DN; Ramesh V; Gusella JF
Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
[TBL] [Abstract][Full Text] [Related]
27. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis type 2.
Evans GR; Lloyd SKW; Ramsden RT
Adv Otorhinolaryngol; 2011; 70():91-98. PubMed ID: 21358190
[TBL] [Abstract][Full Text] [Related]
29. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.
De Vitis LR; Tedde A; Vitelli F; Ammannati F; Mennonna P; Bono P; Grammatico B; Grammatico P; Radice P; Bigozzi U; Montali E; Papi L
Hum Genet; 1996 May; 97(5):638-41. PubMed ID: 8655145
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
32. New developments in neurofibromatosis type 2 and vestibular schwannoma.
Ren Y; Chari DA; Vasilijic S; Welling DB; Stankovic KM
Neurooncol Adv; 2021; 3(1):vdaa153. PubMed ID: 33604573
[TBL] [Abstract][Full Text] [Related]
33. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
34. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
35. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
36. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Chen J; Landegger LD; Sun Y; Ren J; Maimon N; Wu L; Ng MR; Chen JW; Zhang N; Zhao Y; Gao X; Fujita T; Roberge S; Huang P; Jain RK; Plotkin SR; Stankovic KM; Xu L
Nat Protoc; 2019 Feb; 14(2):541-555. PubMed ID: 30617350
[TBL] [Abstract][Full Text] [Related]
37. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
38. Bilateral Vestibular Schwannomas in a Patient with Ring Chromosome 22: Case Report and Review of the Literature.
Nussbaum PE; Patel PD; Nussbaum LA; Hilton CW; Nussbaum ES
Pediatr Neurosurg; 2021; 56(1):56-60. PubMed ID: 33550291
[TBL] [Abstract][Full Text] [Related]
39. Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas.
Shi J; Lu D; Gu R; Xie J; Yu L; Sun X; Zhang Y
World Neurosurg; 2022 Jan; 157():e66-e76. PubMed ID: 34587518
[TBL] [Abstract][Full Text] [Related]
40. Genesis and biology of vestibular schwannomas.
Roche PH; Bouvier C; Chinot O; Figarella-Branger D
Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
